Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Current Value
$2.031 Year Return
Current Value
$2.031 Year Return
Market Cap
$293.82M
P/E Ratio
-8.71
1Y Stock Return
8.31%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
2.3
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
SeekingAlpha
Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside with phase 3 and 2b trials ahead.
Yahoo
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controlsSafety continues to be favourable with no new
Yahoo
Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcomaOver three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall survival, as compared to historical results from radiotherapy alone SYDNEY, AUSTRALIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage bi
Yahoo
If you love investing in stocks you're bound to buy some losers. But long term Immutep Limited ( ASX:IMM ) shareholders...
Yahoo
Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial designEfti in combination with MSD’s KEYTRUDA® reports positive efficacy and favourable safety in first-line head and neck cancer in TACTI-003 Phase IIb trialFirst participant successfully dosed in the first-in-human Phase I trial of IMP761, a novel LAG-3 agonist antibody designed to treat autoimmune diseasesImmute
Yahoo
Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it will present new data from Cohort B of the TACTI-003 Phase IIb trial in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression (CPS <1) at the European Society for Medical Onc
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FIZZ | -17.70% | $4.43B | +4.83% | 0.00% |
UUU | -16.56% | $4.97M | -41.89% | 0.00% |
ATEX | -16.36% | $617.94M | +5.94% | 0.00% |
LNN | -13.58% | $1.35B | +3.22% | 1.14% |
IIIV | -13.10% | $550.91M | +13.90% | 0.00% |
AADI | -12.54% | $54.47M | -52.78% | 0.00% |
TCTM | -11.96% | $8.10M | -42.99% | 0.00% |
SAVA | -9.45% | $1.35B | +25.50% | 0.00% |
SUZ | -9.30% | $13.00B | -2.96% | 2.27% |
NHTC | -9.15% | $61.83M | +0.19% | 14.81% |
AMED | -8.76% | $2.95B | -3.95% | 0.00% |
TCS | -8.65% | $14.81M | -84.46% | 0.00% |
HUSA | -8.56% | $16.69M | -11.56% | 0.00% |
TH | -8.49% | $839.02M | -24.49% | 0.00% |
LPTH | -8.43% | $62.27M | +33.05% | 0.00% |
MKC | -8.41% | $20.21B | +15.19% | 2.23% |
MEDP | -8.07% | $9.79B | +14.00% | 0.00% |
NARI | -8.07% | $2.98B | -11.66% | 0.00% |
MUSA | -8.07% | $10.62B | +42.37% | 0.34% |
VRNT | -8.04% | $1.44B | +0.69% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EQC | 0.01% | $2.16B | +6.52% | 0.00% |
AQB | 0.01% | $3.78M | -37.77% | 0.00% |
STOK | -0.02% | $614.95M | +197.69% | 0.00% |
MESO | 0.03% | $1.23B | +347.11% | 0.00% |
PFE | 0.03% | $142.24B | -17.16% | 6.73% |
CHT | -0.04% | $29.51B | +1.71% | 3.86% |
CTO | 0.04% | $588.73M | +19.32% | 7.78% |
VTLE | -0.05% | $1.19B | -32.18% | 0.00% |
HTZ | 0.06% | $568.49M | -52.77% | 0.00% |
PSTG | 0.06% | $16.35B | +36.41% | 0.00% |
VSCO | 0.07% | $2.85B | +71.64% | 0.00% |
LBTYA | -0.07% | $4.57B | +44.50% | 0.00% |
VERX | -0.08% | $7.99B | +89.70% | 0.00% |
AZO | 0.08% | $52.52B | +16.10% | 0.00% |
TGS | 0.09% | $1.97B | +116.04% | 0.00% |
DCOM | -0.09% | $1.52B | +72.79% | 2.89% |
CYH | 0.09% | $529.39M | +35.59% | 0.00% |
YPF | 0.10% | $13.98B | +139.72% | 0.00% |
EDSA | -0.10% | $7.11M | -21.79% | 0.00% |
FOUR | -0.15% | $7.17B | +60.36% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ELAN | 35.02% | $6.58B | +12.99% | 0.00% |
AVAV | 28.95% | $5.50B | +51.29% | 0.00% |
CODX | 28.68% | $34.16M | -25.17% | 0.00% |
FSP | 24.69% | $191.60M | -20.60% | 2.17% |
BVN | 24.04% | $3.16B | +37.49% | 0.00% |
CIG.C | 23.38% | $2.48B | -3.55% | 0.00% |
SEVN | 22.23% | $193.74M | +16.70% | 10.77% |
SM | 22.11% | $5.02B | +16.26% | 1.68% |
EBF | 21.74% | $542.44M | +9.16% | 4.83% |
SHW | 20.93% | $94.07B | +36.54% | 0.77% |
RY | 20.69% | $173.56B | +40.55% | 3.32% |
WOR | 20.65% | $1.94B | -5.56% | 1.27% |
MGEE | 20.61% | $3.78B | +41.56% | 1.66% |
CDE | 20.61% | $2.66B | +143.96% | 0.00% |
FSM | 20.57% | $1.51B | +32.33% | 0.00% |
VSTM | 20.55% | $176.25M | -36.94% | 0.00% |
MITT | 20.42% | $199.19M | +31.07% | 9.79% |
FLUX | 20.33% | $37.37M | -36.18% | 0.00% |
ABX | 20.23% | $30.98B | +9.45% | 2.27% |
JOUT | 20.19% | $328.98M | -37.36% | 4.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -22.06% | $195.31M | 0.85% |
TAIL | -14.20% | $67.98M | 0.59% |
BTAL | -13.66% | $388.04M | 1.43% |
MNA | -12.37% | $220.85M | 0.77% |
HIGH | -12.18% | $302.78M | 0.51% |
EQLS | -11.27% | $76.08M | 1% |
USDU | -11.17% | $201.97M | 0.5% |
PHDG | -10.14% | $113.97M | 0.39% |
KCCA | -8.50% | $220.51M | 0.87% |
CANE | -8.24% | $17.72M | 0.29% |
MINT | -6.89% | $11.62B | 0.35% |
UUP | -6.39% | $309.25M | 0.77% |
CTA | -6.19% | $350.27M | 0.78% |
TBIL | -5.60% | $4.38B | 0.15% |
DBO | -5.49% | $217.57M | 0.77% |
FBY | -4.89% | $127.69M | 0.99% |
FMF | -4.74% | $244.61M | 0.95% |
AGZD | -4.64% | $142.76M | 0.23% |
GBIL | -4.10% | $5.60B | 0.12% |
TBLL | -3.84% | $1.92B | 0.08% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EFAA | 34.97% | $117.38M | 0% |
QQA | 24.66% | $135.01M | 0% |
RSPA | 22.74% | $273.87M | 0% |
EPU | 21.96% | $81.05M | 0.59% |
QAI | 21.65% | $628.22M | 0.91% |
THTA | 21.53% | $32.20M | 0.49% |
PFLD | 21.03% | $457.09M | 0.46% |
YYY | 20.84% | $538.03M | 4.6% |
KXI | 20.74% | $695.03M | 0.41% |
XME | 20.68% | $1.86B | 0.35% |
SDOG | 20.62% | $1.24B | 0.36% |
MXI | 20.49% | $222.22M | 0.42% |
PCEF | 20.44% | $813.14M | 3.08% |
BOTZ | 20.35% | $2.57B | 0.68% |
AOR | 20.35% | $2.20B | 0.15% |
FDVV | 20.29% | $4.10B | 0.15% |
ICLN | 20.12% | $1.69B | 0.41% |
FLTR | 20.06% | $1.79B | 0.14% |
DVY | 20.06% | $20.66B | 0.38% |
IGF | 20.05% | $4.51B | 0.42% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBE | 0.08% | $50.13M | 0.77% |
ICSH | 0.13% | $5.57B | 0.08% |
GSG | -0.15% | $914.42M | 0.75% |
FCOM | 0.48% | $1.30B | 0.084% |
PREF | 0.50% | $999.92M | 0.55% |
PWZ | 0.51% | $697.36M | 0.28% |
XLC | -0.59% | $19.23B | 0.09% |
WEAT | -0.75% | $120.27M | 0.28% |
DBC | 0.82% | $1.39B | 0.87% |
XBIL | 0.83% | $637.70M | 0.15% |
AMDY | -0.83% | $144.24M | 0.99% |
BILZ | -1.00% | $563.02M | 0.14% |
COMT | 1.03% | $829.06M | 0.48% |
VOX | -1.13% | $4.28B | 0.1% |
GCC | 1.13% | $133.23M | 0.55% |
PDBC | 1.46% | $4.40B | 0.59% |
HTAB | 1.58% | $437.10M | 0.4% |
XHLF | -1.66% | $874.27M | 0.03% |
SEIX | 1.84% | $268.81M | 0.62% |
IBTE | 1.87% | $1.70B | 0.07% |